Saatja: "ola" <
[email protected]>
Teema: WHO: C.L.5.2026 (Proposed INN list 134)
Kuupäev: 2026-02-18 15:08
Tähelepanu! Tegemist on välisvõrgust saabunud kirjaga.
Tundmatu saatja korral palume linke ja faile mitte avada.
Dear Member States of the World Health Organization,
Please find attached, in the six official languages, C.L.5.2026 regarding
the proposed list 134 of International Nonproprietary Names for
Pharmaceutical Substances.
Should you have questions regarding C.L.5.2026 please send an email to
<mailto:
[email protected]>
[email protected]
Best regards,
Department of Governing Bodies
World Health Organization
***DO NOT RESPOND TO THIS E-MAIL. YOU WILL NOT RECEIVE A REPLY***
20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT
Ref.: C.L.5.2026
The World Health Organization presents its compliments and has the honour to transmit, in
accordance with Article 3 of the “Procedure for the Selection of Recommended International
Nonproprietary Names for Pharmaceutical Substances”, 1 the following lists of proposed
International Nonproprietary Names (prop. INN) which have been published by the World
Health Organization in WHO Drug Information, Vol. 39, No. 4, 2025 on the WHO website at:
WHO Drug Information, vol. 39, 4 [full issue]:
– p.INN list 134 from p. 1131 to 1420 (deadline for objecting and commenting is
29 May 2026)
It would be appreciated if this communication could be forwarded to the appropriate patent
and trade-mark office and to any other organization dealing with the introduction of
nonproprietary names for pharmaceutical substances. Any comments that may be made, or
notifications of a conflict between proposed names and existing proprietary rights, should be
addressed to the INN Programme (
[email protected]), World Health Organization,
1211 Geneva 27, within four months following the publication of the above-mentioned journal.
The selection of international nonproprietary names by the World Health Organization for
use in all Member States presents many difficulties. It would therefore be appreciated if this
were borne in mind when it is contemplated to exercise the right to raise objections.
Furthermore, the World Health Organization would be grateful if, in the interest of public
health and pursuant to the procedure referred to in the first paragraph of this communication, the
lists of names could be granted protection in Member States during the period they are under
consideration by the World Health Organization as international nonproprietary names.
GENEVA, 17 February 2026
1
Annex to resolution EB15.R7, Off. Rec. Wld Hlth Org., No. 60, pp. 3 and 55. This text was amended by
resolution EB43.R9, Off. Rec. Wld Hlth Org., No. 173, p. 10 and resolution EB115.R4, Executive Board,
115th Session, Resolutions and Decisions (EB115/2005/REC/1), p. 2.